Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND-9041 in Advanced EGFR-Mutated NSCLC
NCT06521034Phase 2Completed
- Sponsor
- Yongchang Zhang
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of FHND-9041 in non-small cell lung cancer (NSCLC), sponsored by Yongchang Zhang. Started Jun 2019; status: completed.
02
Drugs
FHND-9041
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06521034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521034.